CTO
CTO Realty Growth, Inc.
stock NYSE

You work as part of the C-suite? CEO/CFO/CTO, etc

I love that you did this because this should have been part of the real post. I put $100 on Lordstown Motors beccause the CTO was a friend of mine and I wanted to see that company do well. Well they didnt and I learned something about investing that day. Last time I checked 100 turned into $7. lol Oh well.

Oh is that so? Not one fucking piece of data has come out of yours. I have proven my thesis. it is is the 10k. it is in public tweets from the CTO that he is a UFOlogist. You say they have prototypes, they have proof. Where is it? You're the one coming up fucking short.
Make fun of the grok link, it has primary sourcing for everything, including his literal books on how he believes the martians existed but blew themselves up with nuclear bombs. The guy is a psycho.
Hawkins narrowly dodging an SEC violation is on the public record. He was back dating options to give stocks to his buddies and skated out of it by the skin of his teeth.
You got grifters, you got crackpots, and still, not a single shred of evidence that these guys have a working model - because they don't, because it's near impossible.
If fusion is going to originate from anywhere it will be from the Ignition lab at Lawrence Livermore. Not the basement of a UFOlogist.

Oh, so it’s good and normal for a business CTO to be a UFOlogist? That’s a good sign?
Where did I say any single false thing?
No working model
No prototype
No proof.
Just the word of a guy who thinks the govt is out to get him because he believes in antigravity and martians.
At a certain point, you can’t call these mere personal attack but actual devastating liabilities.

Telescope Innovations Corp. is a **Vancouver-based chemical technology company**, not an astronomy/telescope company. It builds **AI- and robotics-enabled lab automation platforms** for pharmaceutical, specialty chemical, critical minerals, and advanced materials R&D. The company was founded in Vancouver in 2019, began full operations in 2022, and grew out of University of British Columbia research led by Prof. Jason Hein.
Its core products and platforms are:
* **DirectInject-LC™**: an online chemical sampling and analysis system that connects live reactions to HPLC instruments, helping chemists monitor reactions and optimize processes faster.
* **Self-Driving Labs (SDLs)**: automated chemistry platforms combining robotics, online/process analytics, and machine-learning decision-making to run and optimize experiments with less manual work.
* **Process development technologies**: especially in scalable pharmaceutical chemistry and battery-material processes such as lithium carbonate and lithium sulfide production.
The company is publicly listed as **CSE: TELI**, **OTCQB: TELIF**, and **FSE: J4U**. Its management includes Henry Dubina as Chairman & CEO and Prof. Jason Hein as Director & CTO.
# Key partnerships and collaborations
**METTLER TOLEDO** — Telescope signed a global distribution agreement for DirectInject-LC™ in February 2024. The deal gives Telescope access to METTLER TOLEDO’s global sales, service, and technical support infrastructure; the company said DirectInject-LC™ had already been adopted by 13 of the top 20 pharmaceutical companies in its first year of commercialization.
**Pfizer** — Telescope and Pfizer signed a multi-year master collaborative research agreement in July 2024 to develop technologies that could accelerate pharmaceutical R&D using automation, robotics, AI, and Self-Driving Laboratories. In February 2026, Telescope announced installation of its second SDL at Pfizer, completed in January 2026, marking progress from collaborative R&D toward potential wider deployment.
**KPBMA / CAIID in South Korea** — The Korean Pharmaceutical and Biopharmaceutical Manufacturers Association purchased a Telescope Self-Driving Lab for a new R&D facility in Seoul. Telescope described it as Korea’s first SDL for drug development and the foundation for a strategic partnership to support SDL adoption in Korea’s pharmaceutical sector.
**Shimadzu Scientific Instruments** — Telescope announced a technology integration partnership with Shimadzu in February 2024 to pair DirectInject-LC™ with Shimadzu HPLC systems, targeting process analytical technology and real-time chemical reaction monitoring.
**Mott Corporation** — Telescope and Mott signed an MOU in October 2023 to develop a robotic sampling probe for difficult chemical mixtures such as slurries and immiscible liquid-liquid reactions. If successful, Mott would manufacture the final product and Telescope would commercialize it exclusively.
**AGI SDA / AGI Group** — In March 2026, Telescope signed a development and collaboration agreement with AGI SDA to develop next-generation automation- and AI-ready chemical reactor technology. The plan is to integrate Telescope’s reaction-sampling technology into AGI’s reactor systems, and the broader effort involves six major biopharmaceutical companies.
**Standard Lithium** — Telescope has worked with Standard Lithium as an R&D partner on next-generation battery materials. In June 2025, Standard Lithium said lithium hydroxide from its Arkansas demonstration plant had been converted into battery-quality lithium sulfide using a process developed with Telescope; samples were sent to solid-state battery companies in Asia and North America for testing.
**Altillion** — Telescope used its ReCRFT™ recrystallization technology on lithium brines concentrated by Altillion’s ALIX process. The companies reported lithium carbonate purity above 99.9%, positioning the combined flow sheet as a simplified route from brines to battery-grade lithium carbonate.
**Cellmine and University of St Andrews** — Telescope delivered recycled, battery-grade lithium carbonate to Cellmine and Prof. John Irvine’s group at the University of St Andrews for battery fabrication and testing, giving external validation pathways for its ReCRFT™ lithium-recycling process.
**Government and ecosystem partners** — Telescope has also received or been conditionally approved for non-dilutive support from groups such as CICE, NRC, and NRCan for lithium-processing technologies, including ReCRFT™ and DualPure™. It also joined the Arkansas Lithium Technology Accelerator, indicating growing positioning in North American battery-material supply chains.
# Overall positioning
Telescope Innovations sits at the intersection of **lab automation, AI-driven chemistry, pharmaceutical process development, and critical-minerals processing**. Its strategy appears to be to commercialize enabling hardware/software platforms first through partners like METTLER TOLEDO and Pfizer, while using the same automation expertise to develop proprietary processes for battery materials and lithium refining.